Navigation Links
Dehaier Medical Announces First Quarter 2011 Financial Results
Date:5/4/2011

ith diluted EPS of $0.17, based on 3.0 million shares outstanding for the first quarter of 2010. The increase in share count was due to the completion of the Company's initial public offering in April 2010.

Liquidity and Capital ResourcesAs of March 31, 2011, Dehaier had $3.37 million in cash and cash equivalents, compared with $5.92 million as of December 31, 2010. The decrease was primarily due to an increase in prepayments. Current assets totaled $33.90 million, with working capital of $23.15 million and total shareholders' equity of $26.26 million at March 31, 2011, respectively.

Conference Call and WebcastManagement will host a conference call to discuss these financial results on Wednesday, May 4, 2011 at 8:00 a.m. EDT.

To participate in the call please dial (877) 941-1429, or (480) 629-9666 for international calls, approximately 10 minutes prior to the scheduled start time. Interested parties can also listen via a live Internet webcast, which can be found via the Company's website at http://www.chinadhr.com.

A replay of the call will be available approximately 2 hours after the conclusion of the live call, through May 18, 2011. The replay can be accessed by dialing 800-406-7325 in the U.S. and Canada, or 303-590-3030 internationally and entering the passcode: 4437089. In addition, a recording of the call will be available via the company's website at http://www.chinadhr.com for one year.

About Dehaier Medical Systems Ltd.Dehaier Medical Systems is an emerging leader in the development, assembly, marketing and sale of medical products in China, including respiratory and oxygen homecare medical products. The company develops and assembles its own branded medical devices and homecare medical products from third-party components. The company also distributes products designed and manufactured by other companies, including medical devi
'/>"/>

SOURCE Dehaier Medical Systems Ltd.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Dehaier Medical to Report First Quarter 2011 Financial Results on May 4
2. Dehaier Medical Chairman and CEO Issues Letter to Shareholders
3. Dehaier Medical Systems Signs New Distribution Agreement to Distribute eVent Medical Ventilators
4. Dehaier Medical Announces Fourth Quarter and Full-Year 2010 Financial Results
5. Dehaier Medical to Report Fourth Quarter and Full-Year 2010 Financial Results on March 7
6. Dehaier Medical Announces March Investor Presentations
7. Dehaier Medical Retains The Piacente Group as Strategic Investor Relations Consulting Firm
8. Dehaier Medical Announces Participation in Arab Health 2011
9. Dehaier Medical Announces Third Quarter 2010 Financial Results
10. Dehaier Medical Announces Conference Call to Discuss Third Quarter 2010 Financial Results
11. Dehaier Medical to Participate in MEDICA International Trade Fair
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... , July 11, 2014  Kindred Hospital Houston ... announce the opening of its new outpatient wound ... services to people with chronic, hard to heal ... can lead to amputation, lower leg wounds related ... delayed closure, and traumatic injury wounds which are ...
(Date:7/11/2014)... 11, 2014 Research and Markets ( ... "Immunoprotein Diagnostic Testing Market - Forecasts to ... of 6% and is expected to be valued ... offering. http://photos.prnewswire.com/prnh/20130307/600769 ... has been segmented according to immunoprotein types which ...
(Date:7/10/2014)... 11, 2014  Major advances in radiation therapy ... being highlighted in a three-day Oncology Summit taking ... July, 2014.  Renowned national and international cancer experts from ... and exchange knowledge on modern technologies making treatment ... The Summit will address a ...
Breaking Medicine Technology:Kindred Hospital Houston Northwest, With Wound Care Specialists, Opens Outpatient Wound Healing And Hyperbaric Center 2Immunoprotein Diagnostic Testing Market - Forecasts to 2019: Expected to grow at the highest CAGR of 6% and is expected to be valued at USD 4,943.0 million 2Improving quality and access to advanced cancer care in India and South Asia 2Improving quality and access to advanced cancer care in India and South Asia 3Improving quality and access to advanced cancer care in India and South Asia 4Improving quality and access to advanced cancer care in India and South Asia 5
... CHEST 2007 on concomitant use of Perforomist(TM) Inhalation Solution with ... ... treatment-, NAPA, Calif., Oct. 24 Data presented today at,CHEST ... (ACCP), demonstrate concomitant use of nebulized formoterol,fumarate and tiotropium provided improved ...
... Two Major Clinical Studies TAX 323 and TAX ... Sanofi-aventis,announced today that results of two clinical studies ... cisplatin and,5- fluorouracil for induction therapy, significantly improved ... cell carcinoma of,the head and neck (SCCHN) are ...
Cached Medicine Technology:Clinical Trial Data on the Safety and Efficacy of Concomitant Formoterol Fumarate/ Tiotropium Treatment for COPD 2Clinical Trial Data on the Safety and Efficacy of Concomitant Formoterol Fumarate/ Tiotropium Treatment for COPD 3Clinical Trial Data on the Safety and Efficacy of Concomitant Formoterol Fumarate/ Tiotropium Treatment for COPD 4Clinical Trial Data on the Safety and Efficacy of Concomitant Formoterol Fumarate/ Tiotropium Treatment for COPD 5Clinical Trial Data on the Safety and Efficacy of Concomitant Formoterol Fumarate/ Tiotropium Treatment for COPD 6Studies Showing Significant Survival Improvement with Taxotere(R)-based Regimens in the Induction Treatment of Patients with Locally Advanced Head and Neck Cancer are Published in the Same Issue of the New England Journal of Medicine 2Studies Showing Significant Survival Improvement with Taxotere(R)-based Regimens in the Induction Treatment of Patients with Locally Advanced Head and Neck Cancer are Published in the Same Issue of the New England Journal of Medicine 3Studies Showing Significant Survival Improvement with Taxotere(R)-based Regimens in the Induction Treatment of Patients with Locally Advanced Head and Neck Cancer are Published in the Same Issue of the New England Journal of Medicine 4Studies Showing Significant Survival Improvement with Taxotere(R)-based Regimens in the Induction Treatment of Patients with Locally Advanced Head and Neck Cancer are Published in the Same Issue of the New England Journal of Medicine 5Studies Showing Significant Survival Improvement with Taxotere(R)-based Regimens in the Induction Treatment of Patients with Locally Advanced Head and Neck Cancer are Published in the Same Issue of the New England Journal of Medicine 6Studies Showing Significant Survival Improvement with Taxotere(R)-based Regimens in the Induction Treatment of Patients with Locally Advanced Head and Neck Cancer are Published in the Same Issue of the New England Journal of Medicine 7
(Date:7/12/2014)... Recently, iFitDress.com, one of the world’s leading ... red evening gowns . What’s more, all these hot outfits ... The company’s senior spokesman states, “We are proud to announce ... is an enjoyable shopping experience. In addition to the big ... low prices do not always mean bad quality. All the ...
(Date:7/12/2014)... 2014 Fresh off their respective performances in ... meet on September 5th at Sun Life Stadium in an ... some of the brightest stars in the world of football ... will be treated to some of the best talent in ... as the third best team in the world according to ...
(Date:7/12/2014)... By Dennis Thompson ... -- There,s no way to guarantee that a surgical technique ... tiny incisions won,t increase the risk of spreading cancer to ... Friday. The advisory panel to the Food and Drug ... -- called laparoscopic power morcellation -- should sign a written ...
(Date:7/12/2014)... Demand Response Management Systems is a ... reducing the imbalance between energy supply and demand. With ... rolled out (due to increasing pressure on the grid) ... in controlling residential appliances and thermostats for load reduction. ... American region, and with government mandates and benefits for ...
(Date:7/12/2014)... July 12, 2014 Tylenol lawsuits ... to move forward in the federal multidistrict litigation ... Pennsylvania, Bernstein Liebhard LLP reports. According to a ... Lawrence F. Stengel has ordered the deposition of ... Stengel found that the witness’s testimony concerning the ...
Breaking Medicine News(10 mins):Health News:Discounted Red Evening Gown Announced by iFitDress.com 2Health News:Brazil Vs. Colombia Tickets Sun Life Stadium: Ticket Down Slashes Ticket Prices for Friendly Match Between Colombia and Brazil 2Health News:Brazil Vs. Colombia Tickets Sun Life Stadium: Ticket Down Slashes Ticket Prices for Friendly Match Between Colombia and Brazil 3Health News:FDA Advisers Weigh Risks of Procedure for Removal of Uterine Fibroids 2Health News:FDA Advisers Weigh Risks of Procedure for Removal of Uterine Fibroids 3Health News:North America Demand Response Management System Worth $12,522.4 Million by 2019 - New Report by MicroMarket Monitor 2Health News:North America Demand Response Management System Worth $12,522.4 Million by 2019 - New Report by MicroMarket Monitor 3Health News:North America Demand Response Management System Worth $12,522.4 Million by 2019 - New Report by MicroMarket Monitor 4Health News:Tylenol Lawsuit News: U.S. District Judge Overseeing Federal Tylenol Liver Damage Litigation Orders Deposition of Former McNeil President, Bernstein Liebhard LLP Reports 2Health News:Tylenol Lawsuit News: U.S. District Judge Overseeing Federal Tylenol Liver Damage Litigation Orders Deposition of Former McNeil President, Bernstein Liebhard LLP Reports 3Health News:Tylenol Lawsuit News: U.S. District Judge Overseeing Federal Tylenol Liver Damage Litigation Orders Deposition of Former McNeil President, Bernstein Liebhard LLP Reports 4
... , SEATTLE, June 24 Lightspeed Design, Inc. announces ... software for state-of-the-art capture and playback of HD 3D ... hundreds of professional clients in corporate, entertainment, medical and ... into the new DepthQ(R) family of stereoscopic software -- ...
... , Pig jaw workshop gives attendees hands-on experience , ... RIEMSER , a leading manufacturer of bone tissue regeneration ... grafting workshop to be held in Chicago Friday, July 24th ... step-by-step instructions in site preservation, information on bone grafting materials ...
... doubt on notion of moms, unconditional love , ... likely than men to look away from less-than-cute babies, ... a mother,s unconditional love. , The findings might reflect ... healthy offspring, suggest the researchers, from Harvard-affiliated McLean Hospital ...
... OPEN NEXT SPRING IN HOUSTON METROPOLITAN AREA ... Living, Inc. (OTC Bulletin Board: TCSR), which develops, manages and ... a funding agreement with a national lender for the development ... metropolitan area. Funding for Trinity Terrace , an ...
... of Phosphatidylserine-Targeting Antibodies to Image Solid Tumors and Other Malignancies ... Showing Utility of PS-Targeting Antibodies for the Molecular Imaging of ... Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM ) today reported ... vascular imaging applications for phosphatidylserine (PS)-targeting antibodies. The patent ...
... Seventy-Seven Percent of Surveyed Physicians Will Increase Their Use ... a New Report from AMR and Decision Resources , ... /PRNewswire/ -- Arlington Medical Resources (AMR) and ... oral formulation is a leading drug attribute that surveyed ...
Cached Medicine News:Health News:Lightspeed Releases the New DepthQ(R) Family of Stereoscopic HD Video Software 2Health News:Lightspeed Releases the New DepthQ(R) Family of Stereoscopic HD Video Software 3Health News:RIEMSER Announces Upcoming Chicago Bone Grafting Workshop 2Health News:Women More Likely Than Men to Reject Unattractive Babies 2Health News:TrinityCare Senior Living Announces Funding Agreement for Fourth Senior Living Facility 2Health News:Peregrine Pharmaceuticals Awarded Broad New U.S. Patent for Vascular Imaging Applications of Its PS-Targeting Platform 2Health News:Peregrine Pharmaceuticals Awarded Broad New U.S. Patent for Vascular Imaging Applications of Its PS-Targeting Platform 3Health News:Peregrine Pharmaceuticals Awarded Broad New U.S. Patent for Vascular Imaging Applications of Its PS-Targeting Platform 4Health News:Availability in Both Intravenous and Oral Formulation is a Leading Drug Attribute Surveyed Physicians Prefer for the Treatment of Urinary Tract Infections in the Hospital Setting 2Health News:Availability in Both Intravenous and Oral Formulation is a Leading Drug Attribute Surveyed Physicians Prefer for the Treatment of Urinary Tract Infections in the Hospital Setting 3
Measles IgM ELISA test is an enzyme linked immunosorbent assay (ELISA) for the detection of IgG class antibodies to Measles (Rubeola) in human serum or plasma....
... The Diagnostic Automation, Inc.. (DAI) Measles ... for the detection and quantitative determination of ... human sera. Individual serum specimens may ... status. Paired sera, acute and convalescent, may ...
... osmolality at room temperature with the sample ... are cryoscopic artifacts due to high viscosity, ... with freezing point determinations. The superbly accurate ... osmometer has a much broader range of ...
... a glucocorticoid produced by the adrenal cortex ... is secreted with a circadian periodicity, and ... morning. Cortisol is often elevated in major ... AIDS, and in the visceral fat of ...
Medicine Products: